Fusion Antibodies PLC

LSE:FAB UK Biotechnology
Market Cap
$172.86K
GBX1.42 Billion GBX
Market Cap Rank
#47261 Global
#1031 in UK
Share Price
GBX12.50
Change (1 day)
+0.00%
52-Week Range
GBX5.80 - GBX19.25
All Time High
GBX213.00
Categories
Companies in UK Biotechnology
About

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more

Fusion Antibodies PLC (FAB) - Net Assets

Latest net assets as of September 2025: GBX726.00K GBX

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has net assets worth GBX726.00K GBX as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.81 Million) and total liabilities (GBX1.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX726.00K
% of Total Assets 40.07%
Annual Growth Rate 6.45%
5-Year Change -85.91%
10-Year Change -54.08%
Growth Volatility 282.35

Fusion Antibodies PLC - Net Assets Trend (2006–2025)

This chart illustrates how Fusion Antibodies PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Fusion Antibodies PLC (2006–2025)

The table below shows the annual net assets of Fusion Antibodies PLC from 2006 to 2025.

Year Net Assets Change
2025-03-31 GBX669.00K -62.69%
2024-03-31 GBX1.79 Million +59.66%
2023-03-31 GBX1.12 Million -69.52%
2022-03-31 GBX3.68 Million -22.39%
2021-03-31 GBX4.75 Million -1.35%
2020-03-31 GBX4.81 Million -10.12%
2019-03-31 GBX5.35 Million -18.57%
2018-03-31 GBX6.58 Million +285.43%
2017-03-31 GBX1.71 Million +17.08%
2016-03-31 GBX1.46 Million +760.64%
2015-03-31 GBX169.29K +937.34%
2014-03-31 GBX16.32K -67.44%
2013-03-31 GBX50.13K +168.67%
2012-03-31 GBX-73.00K -122.60%
2011-03-31 GBX323.00K -37.16%
2010-03-31 GBX514.00K +173.40%
2009-03-31 GBX188.00K -71.30%
2008-03-31 GBX655.00K +7.73%
2007-03-31 GBX608.00K +198.04%
2006-03-31 GBX204.00K --

Equity Component Analysis

This analysis shows how different components contribute to Fusion Antibodies PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1146700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Common Stock GBX4.20 Million 627.35%
Other Components GBX7.94 Million 1186.70%
Total Equity GBX669.00K 100.00%

Fusion Antibodies PLC Competitors by Market Cap

The table below lists competitors of Fusion Antibodies PLC ranked by their market capitalization.

Company Market Cap
ADVANCED CELL TECH
BE:T2N
 		$2.08K
Trans Asia Hotels PLC
CM:TRANN0000
 		$2.08K
Rome Resources Plc
LSE:RMR
 		$2.08K
OIBR4F
SA:OIBR4F
 		$2.08K
Sky Century Investment Inc
PINK:SKYI
 		$2.07K
Asia Pacific Investment JSC
VN:API
 		$2.07K
ANGANG STEEL -H-
MU:GNV
 		$2.07K
BEC WORLD -F-
MU:BW7
 		$2.07K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Fusion Antibodies PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,793,000 to 669,000, a change of -1,124,000 (-62.7%).
  • Net loss of 1,713,000 reduced equity.
  • New share issuances of 555,000 increased equity.
  • Other factors increased equity by 34,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX-1.71 Million -256.05%
Share Issuances GBX555.00K +82.96%
Other Changes GBX34.00K +5.08%
Total Change GBX- -62.69%

Book Value vs Market Value Analysis

This analysis compares Fusion Antibodies PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1791.47x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 9165.56x to 1791.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-03-31 GBX0.00 GBX12.50 x
2014-03-31 GBX0.00 GBX12.50 x
2015-03-31 GBX0.01 GBX12.50 x
2016-03-31 GBX0.07 GBX12.50 x
2017-03-31 GBX0.08 GBX12.50 x
2018-03-31 GBX0.41 GBX12.50 x
2019-03-31 GBX0.24 GBX12.50 x
2020-03-31 GBX0.22 GBX12.50 x
2021-03-31 GBX0.19 GBX12.50 x
2022-03-31 GBX0.14 GBX12.50 x
2023-03-31 GBX0.04 GBX12.50 x
2024-03-31 GBX0.03 GBX12.50 x
2025-03-31 GBX0.01 GBX12.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Fusion Antibodies PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -256.05%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -87.18%
  • • Asset Turnover: 1.49x
  • • Equity Multiplier: 1.98x
  • Recent ROE (-256.05%) is below the historical average (-174.89%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 -1555.82% -115.74% 1.33x 10.08x GBX-471.75K
2014 0.00% -15.70% 2.30x 0.00x GBX-113.17K
2015 -50.27% -9.36% 2.45x 2.19x GBX-102.04K
2016 79.21% 77.91% 0.79x 1.28x GBX1.01 Million
2017 7.03% 6.27% 0.89x 1.26x GBX-50.64K
2018 -10.65% -26.01% 0.37x 1.10x GBX-1.36 Million
2019 -23.62% -57.95% 0.35x 1.17x GBX-1.80 Million
2020 -14.48% -17.89% 0.64x 1.26x GBX-1.18 Million
2021 -61.07% -69.60% 0.71x 1.23x GBX-3.37 Million
2022 -32.57% -25.01% 0.98x 1.33x GBX-1.57 Million
2023 -231.17% -89.49% 1.41x 1.84x GBX-2.71 Million
2024 -124.15% -195.95% 0.47x 1.35x GBX-2.41 Million
2025 -256.05% -87.18% 1.49x 1.98x GBX-1.78 Million

Industry Comparison

This section compares Fusion Antibodies PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $11,845,915
  • Average return on equity (ROE) among peers: -158.72%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Fusion Antibodies PLC (FAB) GBX726.00K -1555.82% 1.50x $2.07K
4BASEBIO UK SOCIETAS (4BB) $11.70 Million -27.66% 0.26x $10.53K
Aptamer Group PLC (APTA) $8.05 Million -26.00% 0.43x $3.12K
Arecor Therapeutics PLC (AREC) $773.79K -355.70% 4.54x $3.33K
Bioventix (BVXP) $4.20 Million 36.18% 0.07x $9.85K
Cizzle Biotechnology Holdings PLC (CIZ) $741.00K -0.02% 3.16x $747.56
Faron Pharmaceuticals Oy (FARN) $1.61 Million -823.73% 5.34x $27.00K
Futura Medical (FUM) $9.72 Million -50.98% 0.21x $424.60
hVIVO plc (HVO) $2.86 Million -195.31% 2.17x $5.18K
International Biotechnology Trust plc (IBT) $66.95 Million 14.71% 0.00x $997.94